Sign in

CIK 0000899923

  • Accelerated filer

MYRIAD GENETICS INC

Sign in to watch
Ticker
MYGN
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
870494517
Phone
+1 801-584-3600
Business address
322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
Former names
MYRIAD GENETICS INC
  1. 4 Open-market sale Director sold 10,000 shares at $27.05 ($270,520)
  2. 4 Grant or award Chief Legal Officer acquired 61,771 shares (grant or award)
  3. 4 Planned sale Director sold 46,012 shares at $27.95 ($1,285,851)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Shares withheld for taxes Chief Accounting Officer gave up 217 shares (to pay taxes)
  6. 4 Open-market sale SVP, Chief of Staff sold 11,538 shares at $27.82 ($320,987)
  7. 4 Planned sale Director sold 7,500 shares at $28.01 ($210,075)
  8. 4 Shares withheld for taxes President and CEO gave up 73,788 shares (to pay taxes)
  9. 4 Grant or award Director acquired 15,695 shares (grant or award)
  10. 4 Grant or award Director acquired 15,695 shares (grant or award)
  11. 4 Grant or award Director acquired 15,695 shares (grant or award)
  12. 4 Grant or award Director acquired 15,695 shares (grant or award)
  13. 4 Grant or award Director acquired 15,695 shares (grant or award)
  14. 4 Grant or award Director acquired 15,695 shares (grant or award)
  15. 4 Grant or award Director acquired 15,695 shares (grant or award)
  16. 4 Insider Changes in Ownership
  17. 4 Planned sale Director sold 7,576 shares at an average $22.05 ($167,013)
  18. 4 Open-market sale President and CEO sold 227,844 shares at an average $25.14 ($5,728,763)
  19. 4 Open-market sale Director sold 6,200 shares at $25.30 ($156,860)
  20. 4 Shares withheld for taxes Chief Scientific Officer gave up 940 shares (to pay taxes)

Page 7 of 65 · 1,293 filings